American Society of Hematology Annual Meeting & Exposition (ASH)

This interview examines the use of KIR genotyping during donor selection and its association with improved outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

In this interview we discuss advances in the relationship between the microbiome and outcomes after allogeneic transplant, including graft-vs-host disease and relapse.

This video examines different mutational profiles of therapy-related myeloid neoplasms and how they can affect approaches to treatment.

For the first time, a study shows that using an immunomodulatory agent as maintenance therapy prolongs progression-free survival for patients with diffuse large B-cell lymphoma after first-line treatment with rituximab plus CHOP.

A study of pediatric acute lymphoblastic leukemia (ALL) has identified IKZF1 as a new ALL predisposition gene that may play a role both in leukemia pathogenesis and treatment responsiveness.

Ibrutinib can be safely combined with lenalidomide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma, according to a new study presented at the American Society of Hematology 58th Annual Meeting and Exposition, held December 3–6.

This interview examines treatment-related cardiotoxicity and the risk of second malignancy in patients with Hodgkin lymphoma.

This interview examines a study that looked at the health-related quality of life of multiple myeloma patients in a real-world setting who underwent maintenance therapy after autologous stem cell transplant.

This interview examines the role of functional imaging to direct therapy (escalation or de-escalation) for early and advanced Hodgkin lymphoma.

In this video we discuss longer term results of the phase III SABRINA study, which tested the safety and efficacy of subcutaneous rituximab in patients with follicular lymphoma.

We are speaking with Sonali Smith, MD, an associate professor of medicine and the director of the lymphoma program at the University of Chicago. At the ASH meeting, Dr. Smith will give a talk called “Emerging Biology Leading to New Therapies in Follicular Lymphoma.”

Brentuximab vedotin (BV) induces significantly superior clinical outcomes in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) as compared with physician's choice with methotrexate or bexarotene, according to a new study presented at the American Society of Hematology Annual Meeting & Exposition, held December 3–6, 2016.

In this interview, Dr. Ivan Borrello talks about a new approach to treating multiple myeloma at the American Society of Hematology Annual Meeting, held December 3–6, 2016.

Obinutuzumab-based therapy is superior to rituximab-based therapy in patients with previously untreated advanced follicular lymphoma.

Pembrolizumab has good activity, is safe and well-tolerated, and induces durable responses in cutaneous T-cell lymphomas, according to a study presented at the American Society of Hematology Annual Meeting & Exposition.

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.

As part of our coverage of the ASH Annual Meeting held December 3rd to 6th in San Diego, today we are speaking with Kim Nichols, MD, director of the Cancer Predisposition Division at St. Jude Children's Research Hospital. At this year’s meeting, Dr. Nichols will be participating in a session on genetic susceptibility to leukemia.

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with oncologist Nicholas J. Short, MD, of the Division of Cancer Medicine at University of Texas MD Anderson Cancer Center, in Houston.

In this interview we discuss results of the CALGB 10603 RATIFY trial of midostaurin for acute myeloid leukemia presented earlier this month at ASH.

Ponatinib offered a better overall survival for chronic myeloid leukemia patients in chronic phase compared with allogeneic stem cell transplantation.

Real-time classification can identify a previously unrecognized subset of high-risk patients with childhood B-cell acute lymphoblastic leukemia who have excellent chances for cure without further intensification of treatment.

Single-agent ibrutinib resulted in significantly improved outcomes for older patients with chronic lymphocytic leukemia, compared with chlorambucil treatment.

Warfarin is an acceptable alternative to low-molecular-weight heparin for patients with cancer-associated thrombosis, according to a new study.

Patients with relapsed or refractory CLL had significant delays in progression and death when idelalisib was added to bendamustine and rituximab.

A new study validates therapeutic guidelines that recommend anticoagulant dose reductions for thrombocytopenia in cancer patients.

Patients with relapsed/refractory multiple myeloma continue to have deep and durable responses to daratumumab plus lenalidomide/dexamethasone.

The oral BCL-2 inhibitor venetoclax elicited a high rate of response from patients with high-risk relapsed or refractory chronic lymphocytic leukemia with 17p deletion.

Children with acute lymphocytic leukemia and their parents commonly over-report the amount of daily oral chemotherapy the child takes to treat the most common blood cancer in children.

Chimeric antigen receptor T cells can eradicate large burdens of multiple myeloma, according to a new study presented at ASH.

Genetic variants increase the risk of osteonecrosis in children under age 10 with acute lymphoblastic leukemia.